Last updated: February 27, 2026
What is the drug associated with NDC 62135-0494?
NDC 62135-0494 corresponds to Palbociclib (PD-0332991), a CDK4/6 inhibitor marketed as Ibrance. It is approved for HR-positive, HER2-negative advanced or metastatic breast cancer.
Market Overview
Market Size and Demand Trends
The global breast cancer therapeutics market was valued at approximately USD 13 billion in 2022. Palbociclib accounts for a significant proportion of this, driven by its approval for first-line treatment. The drug's sales have increased 15% annually since launch, reaching USD 5.2 billion globally in 2022, with expectations to grow further.
Competitive Landscape
Palbociclib faces competition from:
- Ribociclib (Kisqali): Contains similar indications; expected growth rate of 12% annually.
- Abemaciclib (Verzenio): Grows at roughly 14% annually; gains market share due to distinct side effect profiles.
Market shares are approximately:
| Drug |
Estimated Market Share (2022) |
| Palbociclib |
65% |
| Ribociclib |
20% |
| Abemaciclib |
15% |
Pricing and Reimbursement
In the U.S., list prices are approximately USD 11,000/month per patient. Actual reimbursement varies by payer, with average net prices around USD 9,500/month. Discount programs and rebates reduce net revenue.
In Europe, prices average USD 8,000/month, with some countries enacting price controls.
Regulatory Environment
Palbociclib retains exclusivity until at least 2032 in the U.S. via existing patents, with some patent challenges ongoing. Patent expiry is a key factor in pricing and market penetration.
Patent Status
Primary patents expire in 2032, but secondary patents and formulation exclusivities extend market protection until 2035 in U.S. and Europe.
Price Projections
Short-term (Next 2 Years)
- Price stability expected due to patent protection.
- List price remains around USD 11,000/month in the U.S.
- Reimbursement pressure could lead to net price reductions of 5-7%.
Medium-term (3-5 Years)
- Anticipated patent challenges and biosimilar competition starting 2028.
- Possible price erosion of 20-30%, bringing net prices down to USD 7,500-8,000/month.
- Entry of generics could further reduce prices by 50% or more.
Long-term (Beyond 2028)
- Patent expiration leads to generics entering the market.
- Generics priced 40-60% lower than originators.
- Total market volume could double due to increased adoption, offsetting price declines.
Revenue Forecasts
| Year |
Estimated Global Revenue |
Factors Influencing Revenue |
| 2023 |
USD 5.2 billion |
Patent protection, steady demand |
| 2024 |
USD 5.5 billion |
Price erosion limited, increasing usage |
| 2028 |
USD 4.2 billion |
Patent expiry, biosimilar entry |
| 2030 |
USD 2-3 billion |
Fully mature biosimilar market |
Key Factors Impacting Future Pricing and Demand
- Regulatory approvals for new indications or combinations.
- Patent legal disputes could extend or shorten exclusivity.
- Market penetration of biosimilars and generics.
- Pricing policies in key markets, especially in Europe and emerging markets.
- Health technology assessments (HTAs) influencing reimbursement.
Summary
NDC 62135-0494 (Palbociclib) is a high-value oncology drug with strong current market share and stable pricing due to patent exclusivity. Pricing is expected to decline gradually starting in 2028 as biosimilars enter markets, with significant erosion projected by 2032-2035. Revenue growth will depend on pipeline developments, new indications, and regulatory or legal challenges affecting market exclusivity.
Key Takeaways
- Palbociclib generated USD 5.2 billion in sales in 2022 with stable pricing in the U.S.
- Patent expiry around 2032 will trigger significant price erosion.
- Market share faces competition from ribociclib and abemaciclib.
- Price declines of 20-50% are probable after biosimilar entry starting 2028.
- Overall market volume is expected to rise before patent expiration, cushioning revenue decline.
FAQs
Q1: When does patent protection for Palbociclib expire?
Patent protection is expected to end in 2032, with some secondary patents extending protection until 2035.
Q2: How will biosimilar entry influence the market?
Biosimilars are expected to enter starting 2028, reducing prices by 40-60%, and capturing a significant market share.
Q3: Are there any regulatory hurdles for new indications?
Regulatory approvals depend on clinical trial results; successful expansion could increase demand and support price stability.
Q4: What factors could accelerate Price erosion?
Patent invalidation, legal challenges, and regulatory decisions favoring biosimilar approval could accelerate price declines.
Q5: How does geographic variation impact pricing?
The U.S. maintains higher prices due to less price regulation, while European and emerging markets have generally lower prices due to tighter controls.
References
- Grand View Research. (2023). Breast Cancer Therapeutics Market Size, Share & Trends Analysis.
- IQVIA. (2022). Global Oncology Market Reports.
- FDA. (2022). Approval and Patent Data for Palbociclib.
- European Medicines Agency. (2022). Pricing and Reimbursement Policies.
- MarketWatch. (2023). Oncology Drug Pricing Trends.
